- Gloperba® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
- Gout is a painful arthritic disorder affecting an estimated 9.2 million people in the United States1. As gout cases increase every year, treatment requirements increase. The gout treatment market is projected to be $2.0 billion in the U.S. by 2028 with a well-defined area of unmet need.2
- Over 70% of gout patients have comorbid conditions that may require dose adjustments and such patients could be a potential target population for Gloperba®3
- Over 17% of gout patients on colchicine experienced severe gastrointestinal side effects like diarrhea. These patients may benefit from flexible dosing offered by Gloperba®4
- Scilex is well-positioned to market and distribute its third commercial non-opioid product, Gloperba®:
- Scilex has a direct distribution network to national and regional wholesalers and pharmacies throughout the U.S.
- Scilex has an experienced commercial and managed care team that has successfully launched and grown market access for ZTlido® (lidocaine topical system) 1.8% to more than 225 million covered lives in the U.S. as well as successfully launching Elyxyb® (celecoxib oral solution) in the U.S. in April 2023, the only FDA-approved ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.
Israeli Court Rejects Bistricer’s Murchinson Motion In Lawsuit Filed By Nano Dimension Respect To Their Illegal Shareholder Meeting
Nano Dimension Ltd. (NASDAQ:NNDM, ", Nano Dimension", or the ", Company", )))), a leading supplier of Additively Manufactured Electronics ("AME") and multi-dimensional
